title: Activated partial thromboplastin time (aPTT) monitoring to achieve therapeutic anticoagulation before and after introducing a nomogram for adjunctive heparin treatment with thrombolytic therapy for acute myocardial infarction.
abstract: In patients with acute myocardial infarction (AMI) receiving thrombolytic therapy and i.v. unfractionated heparin, anticoagulant levels are frequently outside the target range. We evaluated the effects on anticoagulant levels before (group A) and after (group B) the introduction of a heparin nomogram in consecutive AMI-patients, receiving thrombolytic therapy and adjunctive heparin treatment. The target activated partial thromboplastin time (aPTT) was defined as 60-90 s. During the first 72 h after admission, the total number of aPTTs within the target range and the time taken to achieve the range were compared. The incidence of bleeding complications was assessed. Group A consisted of 56 and group B of 55 patients. The number of patients within the target range at 72 h (44 versus 51; chi2=4.51; P=0.034) was significantly higher in group B. No difference was found between total aPTTs within the target range (26% in group A versus 30% in group B; P=ns). Bleeding complications were slightly less in group B (7 versus in group A versus 2 patients in group B; P=ns). We concluded that the introduction of a nomogram resulted in significantly more patients with aPTTs within the target range. However, a substantial number of aPTTs before and after introduction of the nomogram were outside the target range. Moreover, this retrospective study shows that previously acquired prospective data (which showed a marked improvement of anticoagulation using a heparin nomogram) are not necessarily reproduced in the real life clinical setting.
authors.affiliation: Academic Medical Center, Department of Cardiology, University of Amsterdam, The Netherlands. s.a.chamuleau@amc.uva.nl
authors.forename: S A
authors.initials: SA
authors.lastname: Chamuleau
authors.forename: R J
authors.initials: RJ
authors.lastname: de Winter
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D012189:Retrospective Studies; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator